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Glioblastoma multiforme (GBM) is a commonly occurring brain tumor with a poor prognosis. GBM can develop both “de novo”
or evolve from a previous astrocytoma and is characterized by high proliferation and infiltration into the surrounding tissue.
Following treatment (surgery, radiotherapy, and chemotherapy), tumors often reappear. Glioma-initiating cells (GICs) have been
identified in GBM and are thought to be responsible for tumors initiation, their continued growth, and recurrence. β-catenin, a
component of the cell-cell adhesion complex and of the canonical Wnt pathway, regulates proliferation, adhesion, and migration
in diﬀerent cell types. β-catenin and components of the Wnt canonical pathway are commonly overexpressed in GBM. Here, we
review previous work on the role of Wnt/β-catenin signalling in glioma initiation, proliferation, and invasion. Understanding the
molecular mechanisms regulating GIC biology and glioma progression may help in identifying novel therapeutic targets for GBM
treatment.
1. Introduction
Gliomas are the most common primary malignancies in the
central nervous system, comprising a heterogeneous group
of tumors that display some histological similarities to glia
(mainly, astrocytes in astrocytomas and oligodendrocytes in
oligodendrogliomas). Astrocytomas account for the majority
of gliomas, which can be classified into four diﬀerent
grades according to the World Health Organization (WHO)
classification system [1, 2]: grade I and grade II astrocytomas
are slow-growing less aggressive tumors, whereas grade III
and IV gliomas are malignant tumors characterized by high
proliferation rate (grade III) and the presence of necrotic
tissue and/or angiogenic activity (grade IV). The most
malignant form, glioblastoma multiforme (GBM, grade IV),
is one of the most aggressive and lethal forms of cancer
with an average survival time of 15 months after diagnosis
[3, 4]. Standard treatment consists of surgical removal of
the tumor, followed by chemotherapy and radiotherapy.
Temozolomide, an oral alkylating agent, is the most com-
monly used chemotherapy treatment [5]. Importantly, a high
infiltration capacity of individual cells over long distances,
already present in grade II gliomas, hinders complete tumor
resection and most likely contributes to recurrence [6].
GBMs can present as primary or secondary. Primary or
“de novo” GBMs, representing the majority of GBM cases,
arise without any prior evidence of a lower-grade precursor
lesion and more commonly aﬀect older patients (mean age
of 62 years). Secondary GBMs progress from a lower-grade
glioma and typically develop in younger patients (median
age of 45 years). Gliomas exhibit a vast array of genetic
changes that contribute to the malignant phenotype [6–
10]. These include loss of function mutations in the p53
tumor suppressor and hyperactivation of receptor tyrosine
kinase (RTK) signalling, such as epidermal growth factor
receptor (EGFR), platelet-derived growth factor receptor
(PDGFR), and the receptor for hepatocyte growth factor c-
Met. The signalling cascades downstream of activated RTK
often result in activation of Ras and AKT. Mutations in
tumor suppressors such as phosphatase and tensin homolog
(PTEN) and neurofibromatosis 1 (NF1) that normally con-
trol these pathways further contribute to oncogenesis [2,
3, 6–10]. Based on its gene expression profile, GBM can
be further classified into proneural, neural, mesenchymal,
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and classical types [8, 9]. This classification should allow
a molecular stratification of GBM cases with important
therapeutic implications.
Here we focus our attention onWnt/β-catenin signalling,
a pathway primarily involved in embryogenesis and display-
ing important functions in adulthood when aberrant Wnt
signalling has been linked to disease and cancer [11–14].
Understanding how β-catenin signalling regulates gliomage-
nesis and tumor progression may lead to novel therapeutic
interventions in GBM. Firstly, therefore, we discuss the role
of glioma-initiating cells (GICs), a type of “cancer stem cells,”
in glioma development and evidence suggesting that Wnt/β-
catenin signalling regulates GICs biology. We then review
progress in the understanding of the involvement of Wnt/β-
catenin signalling in the proliferation and invasion of glioma
tumor cells.
2. Glioma-Initiating Cells (GICs) and
Signalling Pathways in GICs
The existence of brain tumor stem cells was proposed about
a decade ago, following advances in the stem cell field and
the discovery that neurogenesis persists in the adult brain
[15–18]. Glioma-initiating cells (GICs) share the features
of neural stem cells that have been identified in GBM,
including the expression of CD133 (prominin), the ability
to form neurospheres, and the reproduction of tumors
[19, 20]. However, the role of CD133+ and CD133− GIC
subpopulations in tumor initiation is not clear. CD133− cells
from the C6 glioma cell line showed clonogenic, self-renewal,
and tumorigenic capacities [21]. Nonetheless, CD133−GICs
isolated from primary GBM were as capable of producing
tumors as CD133+ cells [22]. Individual GBM may contain
CD133+ and CD133− GICs that represent diﬀerent stages
of diﬀerentiation [23]. Furthermore, multipotent CD133+
GICs contain a CD144+ (vascular endothelial cadherin pos-
itive) subpopulation that can give rise to tumor endothelial
cells [24].
Signalling by several morphogens and cytokines (includ-
ing leukemia inhibitory factor (LIF), fibroblast growth factor
(FGF) andmembers of theWnt, transforming growth factor-
β (TGF-β)/bone morphogenetic proteins (BMP) families)
maintains the self-renewal capacity of embryonic stem cells
and supports cancer stem cell growth [25]. Thus, TGF-β
signalling through the induction of LIF and the JAK-STAT
pathway promotes the self-renewal of patient-derived GICs
[26]. Seoane and coworkers recently identified a population
of CD44 high/Id1 high GICs in GBM that locates in the
perivascular niche. Depletion of this cell population by
TGF-β inhibitors prevents tumor initiation and recurrence.
This work identifies CD44 and Id1 levels as prognosis
markers in GBM and shows that TGF-β signalling is key
to maintain this GIC population [27]. Aberrant activation
of sonic hedgehog signaling (another morphogen involved
in embryogenesis and brain development) in committed
cerebellar granule neuron precursors is responsible for
aggressive medulloblastoma, a pediatric cerebellar tumor
[28–30]. Hedgehogs signal through Gli transcription factors,
with Gli1 and Gli2 acting as activators and Gli3 as a repressor
factor. Consistent with the isolation of Gli1 from glioma
cells, activation of the Hedgehog-Gli1 pathway is reported in
GBM, which is required for the clonogenicity and formation
of secondary neurospheres of CD133+ GICs [31].
Wnt factors are a family of secreted glycoproteins (19
members exist in humans) that regulate embryonic pat-
terning and play diﬀerent roles throughout development of
the nervous system [32, 33]. Wnts signal through at least
three diﬀerent pathways [11, 33], the best known being the
Wnt/β-catenin canonical pathway (Figure 1). In the absence
of Wnt, the Ser/Thr kinase glycogen-synthase kinase (Gsk-
3β) in the so-called destruction complex (comprising of
Gsk-3β, adenomatosis polyposis coli (APC), Axin and β-
catenin) phosphorylates β-catenin, which is then targeted for
proteasomal degradation. UponWnt binding to Frizzled (Fz)
(of which there are 11 family members in humans) and low-
density-lipoprotein-related protein (LRP)5/6 receptors, the
scaﬀolding protein Dishevelled (Dvl) and LRP5/6 become
phosphorylated by Gsk-3 and Casein-Kinase Iγ. Conse-
quently, the destruction complex components are recruited
instead to the receptor complex, leading to β-catenin stabi-
lization [34]. The protooncogene Frat/GBP further prevents
the phosphorylation and degradation of β-catenin because
it competes with Axin to bind Gsk-3 and removes it from
the destruction complex. Stabilized β-catenin translocates
to the nucleus, where it binds to lymphoid enhancer
factor-1 Lef-1/T-cell factor (Tcf) transcription factors and
regulates expression of Wnt target genes. In the absence of
nuclear β-catenin, Tcf/Lef factors suppress the expression
of target genes through their binding to members of the
Groucho/transducin-like enhancer of split (TLE) family of
transcriptional corepressors. β-catenin does not have a DNA
binding domain but it has a potent transcription activation
domain. Conversely, Lef/Tcf transcription factors do not
have a strong transcription activation domain, but they do
have a good DNA binding/bending domain [35]. Thus, when
β-catenin binds to a Lef/Tcf protein, a potent transcription
regulatory complex is formed. Nuclear translocation of β-
catenin converts Tcf proteins into potent transcriptional
activators by displacing Groucho/TLE and recruiting an
array of coactivator proteins, including CBP, TBP, BRG1,
BCL9/PYGO, Legless, Mediator, and Hyrax [36] (Figure 1).
Canonical Wnt/β-catenin signalling is crucially involved
in embryonic development and controls stem cell biology,
thus inducing self-renewal properties in embryonic stem
(ES) cells and regulating adult stem cells [11, 14, 33, 41–
45]. Nanog and Oct-4, two of the four transcription factors
required to generate the pluripotency and self-renewal of ES
cells, are Tcf3 targets [46, 47]. Interestingly, the ES signature
characterized by the expression of Nanog, Oct-4, Sox-2,
and c-Myc also associates with aggressive tumors, including
poorly diﬀerentiated GBM [37]. As aberrant activation
of the Wnt/β-catenin signalling pathway is a hallmark of
many tumors [12, 14], these findings suggest that Wnt-
regulated genes may contribute to the stem cell-like phe-
notypes displayed by brain tumors. Furthermore, the novel
protooncogene PLAG2 is amplified in GBM and promotes
GICs proliferation and gliomagenesis. PLAG2 increases
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Figure 1: Wnt/β-catenin signalling and β-catenin role in adhesion in glioma cells. (a) In the absence of Wnt ligands or in the presence of
Wnt antagonists Dkk and sFRP that bind to the respective Wnt receptors Fz and LRP5/6, β-catenin is in a complex together with Axin, APC,
and Gsk-3β. Here, β-catenin is phosphorylated by Gsk-3β in key Ser and Thr residues and is thus targeted for proteasomal degradation.
Frat prevents the phosphorylation of β-catenin. Transcription by Lef/Tcf is oﬀ due to the binding of repressors. In the absence of growth
factor signaling, a pool of β-catenin is engaged in the cadherin/β-catenin/α-catenin complex that is linked to the cytoskeleton. (b) Following
Wnt binding, the Fz-LRP5/6 complex is formed upon Dvl phosphorylation that recruits Gsk-3β, Axin, and APC to the membrane. This
results in free β-catenin that accumulates in the cytosol and translocates to the nucleus, where it binds to Tcf and recruits transcriptional
activators (including Pygo). Lef/Tcf transcriptional activation results in the regulation of Wnt target genes. The box shows Wnt target genes
implicated in proliferation and invasion of glioma cells or conferring ES cell signature to GICs that might be related to aggressive growth and
recurrence [37–39] EGF signalling through EGFR, ERK1/2, and CK2 results in the phosphorylation of α-catenin and promotes β-catenin
transactivation [40]. Whether the Wnt-induced and growth factor-induced β-catenin nuclear pools collaborate in glioma cells remains to be
studied. Text in red indicates Wnt pathway components that are overexpressed and green indicates Wnt antagonists repressed in high-grade
astrocytomas and GBM. Wnt factors and Fz that have been reported to be upregulated in high-grade astrocytomas and GBM are shown (see
references in the text).
the˜expression of Wnt-6, Fz-9, and Fz-2, inhibits diﬀerenti-
ation, and increases proliferation of neural progenitors [48].
It is worth noting that PLAG2 amplification correlates with
increased β-catenin levels in GBM samples. These results
indicate that PLAG2 imparts stem-cell properties to glioma
cells by regulating Wnt signalling. Another gene regulating
Wnt signalling in glioma is PEG3 (paternally expressed gene
3), an imprinted gene with a tumor suppressor activity.
Hypermethylation of PEG3 promoter in glioma decreases
PEG3 mRNA expression and correlates with high-grade
gliomas [49]. In turn, low PEG3 expression increases β-
catenin that promotes the proliferation of CD133+ GICs
[49]. Finally, the interaction between the transcription
factor Forkhead box M1 and β-catenin that promotes β-
catenin nuclear localization in tumor cells and maintains
GIC self-renewal has been recently described [50]. Novel
therapeutic interventions for GBM could inhibit Wnt/β-
catenin signalling in GICs to decrease GIC proliferation and
stop glioma growth, while increasing GICs diﬀerentiation.
3. Targeting GIC Chemoresistance and
Radioresistance Mechanisms as an Approach
to Treat GBMRecurrence
Following surgery, chemotherapy, and radiotherapy GBM
recurrence is common. Therefore, a particularly relevant fea-
ture of the cancer stem cells is their ability to export
drugs and develop resistance mechanisms to cytotoxics and
irradiation [17]. Current knowledge suggests that resistance
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to temozolomide is promoted by enhanced O-6-methylgua-
nine-DNA-methyltransferase- (MGMT-) mediated DNA re-
pair of mismatches [51]. Thus, MGMT promoter methyla-
tion status improves the benefits of chemotherapy. Accord-
ing to Liu et al., CD133 expression in tumor tissue is higher
in recurrent GBM than in newly diagnosed tumors and
CD133+ GICs are chemoresistant to temozolomide [52].
However, these findings are inconsistent with a report indi-
cating that CD133+ GICs are depleted after temozolomide
treatment [53]. Consequently, at present it is not clear which
glioma cells are responsible for the resistance to temozolo-
mide.
Another mechanism of drug resistance is the expression
of the ATP-binding cassette (ABC) transporters by cancer
stem cells. BCRP1 and MDR1 ABC transporters allow the
exclusion of Hoechst 33342 dye, a feature that defines the
pluripotential side population (SP) originally reported in
haematopoietic stem cells and now used to identify cancer
stem cells. Expression of these ABC transporters accounts
for the chemoresistance of some cancers and high drug ef-
flux capacity. CD133+ GICs express higher levels of BCRP1
compared to CD133− cells [52]. Consistent with this, a
cancer stem-cells cell line (WJ2) derived from GBM showed
increased expression of BCRP1, CD133 and the neural pre-
cursor marker Nestin and at the same time maintained Wnt-
1 expression [54]. Interestingly, overexpression of MDR1
downstream of Wnt-1/Fz-1 signalling mediates chemoresis-
tance in neuroblastoma cells [55]. This suggests that a similar
mechanism could be operating in the chemoresistancemech-
anisms of gliomas.
As regards radioresistance, the CD133+ stem cell fraction
is enriched after glioma radiation [56]. Furthermore, the
CD133+ subpopulation is able to repair radiation-induced
DNA damage more eﬃciently than CD133− tumor cells
[57]. These results indicate that the CD133+ tumor cell
population confers radioresistance to GBM and most likely
accounts for glioma recurrence. Wnt-1 ectopic expression
triggers DNA damage response in epithelial mammary cells
[58], while activation of Wnt/β-catenin signalling confers
radioresistance to mammary progenitors cells through sur-
vivin upregulation [59]. In addition, Gsk-3β inhibition
enhances DNA repair of double-strand breaks following ra-
diation of hippocampal neurons [60]. Taken together, these
findings suggest that Wnt signalling may be involved in the
chemo- and radioresistance mechanisms developed by GICs.
Expanding our understanding of the molecular mechanisms
supporting GICs resistance to conventional glioma treatment
will allow the design of novel therapeutic tools to decrease
tumor recurrence and improve patient survival.
4. Wnt/β-Catenin Signalling in
the Proliferation of Glioma Cells
GICs represent a small percentage of the brain tumor mass,
which is thought to contain a heterogeneous mixture of
tumor cells with limited proliferation capacity. Molecular
analysis on whole tumor samples is expected to mainly
represent non-GIC cells. Wnt/β-catenin signalling plays a
role in the proliferation of glioma tumor cells and tumor
progression. β-catenin has been proposed as a prognostic
marker in GBM, as both mRNA and protein levels increase
in high-grade astrocytomas and GBM, thus correlating with
malignancy [38, 61, 62]. In addition, the expression of other
positive regulators of the Wnt pathway (including Dvl-3,
FRAT-1, Pygo-2, Tcf4, and Lef-1) [38, 63, 64] and of Wnt
target genes (namely the regulators of cell proliferationCyclin
D1 and c-myc) [38, 62] also increases in high-grade astrocy-
tomas and GBM (see Figure 1). Using immunohistological
techniques, a nuclear fraction of β-catenin was observed
that associates with high-grade astrocytoma and GBM [62].
This result suggests increased cytoplasmic stabilization of β-
catenin that escapes proteasomal degradation, in addition
to the elevated β-catenin mRNA levels reported in GBM.
Silencing β-catenin, Wnt-2, and Pygo-2 expression demon-
strated the involvement of Wnt/β-catenin signalling in the
proliferation of U251 glioma cell line [63, 65]. Together,
these findings point to the activation of nuclear β-catenin
signalling as a mediator of Wnt-induced proliferation of gli-
oma cells. Moreover, expression of noncanonical Wnt-5a is
also upregulated in high grade gliomas, in which Wnt-5a
stimulates cell proliferation [66]. Wnt-5a signalling can in-
hibit canonical Wnt signalling during development [67, 68].
How Wnt canonical and noncanonical pathways interact in
glioma cells remains to be studied.
In contrast to other cancers, no mutations have been
found in β-catenin exon 3, a hot spot aﬀecting the GSK-3
phosphorylation sites and β-catenin degradation that ren-
ders β-catenin active in glioma samples and cell lines [69,
70]. Truncation of APC, a mechanism causing polyposis
and predisposing for Wnt/β-catenin-driven colorectal car-
cinoma, has not been associated with gliomagenesis (with
the exception of Turcot syndrome patients) [71]. These ob-
servations suggest the deregulation of the pathway by unbal-
anced ligand/antagonist expression during tumor initiation
and progression. Indeed, in addition to regulation of the
expression of Wnt family members, Wnt antagonists often
appear repressed in GBM (Figure 1). Expression of the Wnt
antagonist and tumor suppressor Wnt inhibitory factor
(WIF) decreases with malignancy in astrocytomas, which
has been linked to aberrant promoter hypermethylation
[72]. Also, hypermethylation of the secreted-Frizzled-related
protein (sFRP) promoters is a significant event in primary “de
novo” GBM, whereas hypermethylation of the promoter of
the LRP antagonistDickkopf (Dkk) associates with secondary
GBM [70]. Similar epigenetic modifications are common
to other Wnt-driven cancers [73, 74]. In addition, a novel
mechanism for β-catenin nuclear localization and transcrip-
tional activation (both constitutive and Wnt-induced) that
controls Wnt target gene expression and glioma tumorige-
nesis has been described, which involves the interaction of
β-catenin with FoxM1 [50].
5. β-Catenin andWnt Signalling in
Glioma Invasion
As a component of the cell adhesion complex, β-catenin
binds to cadherin, thus regulating cell-cell adhesion. Altering
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the binding of β-catenin to cadherin or to α-catenin down-
regulates cell adhesion, while promoting cell migration and
epithelial-mesenchymal transition [75]. However, β-catenin
nuclear signalling is not only achieved by Wnt factors in
tumor development [76]. Growth factor signalling can in-
duce the phosphorylation of specific tyrosine residues of β-
catenin, resulting in increased migration [75, 77–79]. EGFR
expression is upregulated in primary GBM correlating with
malignancy [15]. EGF/EGFR signalling through extracellular
signal-regulated kinases 1/2 (ERK1/2) and casein kinase-
2 (CK2) in glioma cells results in the phosphorylation of
α-catenin at serine 641, which correlates with glioma ma-
lignancy [40]. Interestingly, α-catenin phosphorylation pro-
motes β-catenin transactivation and glioma cell invasion
[40]. These results highlight the involvement of β-catenin
signalling not only as a mediator of Wnt but also down-
stream of growth factor signalling in glioma invasion. On
the other hand, enhanced expression of the Fz antagonist
sFRP2 reduced glioma invasion by decreasing β-catenin ty-
rosine phosphorylation and downregulating matrix metal-
loprotease-2 (MMP-2) [39]. However, sFRP2 did not aﬀect
β-catenin levels, its cytoplasmic/nuclear distribution, or its
serine phosphorylation status [39]. How sFRP2 signalling
modulates β-catenin tyrosine phosphorylation requires fur-
ther investigation.
Noncanonical Wnt-5a, which signals through β-catenin
independent pathways (including the planar cell polarity and
the calcium pathways [33]), enhances the migration of gli-
oma cells by regulating the expression of MMP-2 [80]. More-
over, silencing the expression of Wnt-2, Wnt-5a, and Fz-
2 in the U251 glioma cell line decreases invasion [65, 80].
These findings are consistent with Wnt-5a function in inva-
sion and metastasis in other cancers [11, 81, 82]. Together,
these results point to metalloprotease regulation as impor-
tant downstream targets of β-catenin and Wnt signalling
pathways in glioma invasion [39, 80, 83].
We are accumulating knowledge on the signalling path-
ways responsible for the maintenance of GICs, sustaining
the proliferation of bulk tumor cells and dictating the inva-
sive properties of glioma cells. Current and future research
should oﬀer novel opportunities for anticancer drug dis-
covery. Undoubtedly, the cancer stem cell hypothesis has
provided a promising framework for investigations into an
incurable disease. Future combined therapies including cyto-
toxics, tumor-targeted drugs, and agents that target GICs
should be expected to reduce glioma growth and recurrence,
raising hopes for glioma patients.
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